Loading…

INNV-13. PREDICTION OF MGMT METHYLATION FOR GLIOBLASTOMAS USING AI MODELS. A COST-EFFECTIVE FRAMEWORK FOR LOW AND MIDDLE-INCOME COUNTRIES

Abstract BACKGROUND MGMT methylation (MGMTmet) is prognostic and predictive for patients with glioblastoma (GBM). However, financial constraints limit access to molecular tests, especially in low and middle-income countries. Artificial intelligence (AI) tools have emerged as a potentially cost-effec...

Full description

Saved in:
Bibliographic Details
Published in:Neuro-oncology (Charlottesville, Va.) Va.), 2023-11, Vol.25 (Supplement_5), p.v158-v159
Main Authors: Restini, Felipe, Yoshimoto, Fernanda Hayashida, de Brito, Leticia Hernandes, Vaz Nascimento, José Eduardo, Mancini, Anselmo, Mendes de Sousa, Cecilia Feliz Penido, Starling, Maria Thereza Mansur, Hanna, Samir Abdallah, Marta, Gustavo Nader, Neves Junior, Wellington Furtado Pimenta
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page v159
container_issue Supplement_5
container_start_page v158
container_title Neuro-oncology (Charlottesville, Va.)
container_volume 25
creator Restini, Felipe
Yoshimoto, Fernanda Hayashida
de Brito, Leticia Hernandes
Vaz Nascimento, José Eduardo
Mancini, Anselmo
Mendes de Sousa, Cecilia Feliz Penido
Starling, Maria Thereza Mansur
Hanna, Samir Abdallah
Marta, Gustavo Nader
Neves Junior, Wellington Furtado Pimenta
description Abstract BACKGROUND MGMT methylation (MGMTmet) is prognostic and predictive for patients with glioblastoma (GBM). However, financial constraints limit access to molecular tests, especially in low and middle-income countries. Artificial intelligence (AI) tools have emerged as a potentially cost-effective solution for identifying MGMTmet. Therefore, we are investigating if an AI model could select those at higher risk to present positive results for molecular confirmation, thus making a better resource allocation. METHODS We have selected GBM patients from the public image bank, The Cancer Imaging Archive, and we included all patients with a molecular evaluation of MGMTmet. We defined our volume of interest based on the ESTRO-ACROP 2016 guideline for GBM radiotherapy contouring and then extracted the radiomic features. The collected features underwent structured analysis, and a prediction model for MGMTmet was developed. We used a Random Forest algorithm to identify the most relevant features. Subsequently, the dataset was divided into training and validation sets. RESULTS We examined 100 patients with histologically classified high-grade gliomas and wild-type IDH, Sixty-one were unmethylated, and 39 were methylated. In this cohort, over 39,000 features were extracted. To avoid noise and overfitting, the 13 most predictive features were selected. They belong to the following feature classes: demographic, first order, Gray Level Size Zone Matrix, and Gray Level Co-occurrence Matrix. The preliminary model achieved an accuracy of 80% for predicting MGMTmet. CONCLUSION our preliminary results show a promising role for AI models in screening patients for molecular testing. This initiative demonstrates the utilization of research to bridge the public health gap. By sharing experiences and fostering collaboration, physicians can work towards mitigating healthcare inequalities in low-middle-income countries. In our future perspectives, we plan to enhance the algorithm's efficacy by incorporating qualitative human-generated features and expanding our sample size.
doi_str_mv 10.1093/neuonc/noad179.0602
format article
fullrecord <record><control><sourceid>oup_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10639888</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/neuonc/noad179.0602</oup_id><sourcerecordid>10.1093/neuonc/noad179.0602</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1842-cd00f6f6ace67635c32098e52382b0998f4f64bd4ba58dfcb953d07fb60549bd3</originalsourceid><addsrcrecordid>eNqNkd1OgzAYQInRxDl9Am_6ArCWQleuDEJhjUANsC1eNfzqzAYLOBMfwbeWjcXEO6_6pV_OSb4cRblHUEPQwrOmOrRNMWvarERzS4ME6hfKBJk6Vk1KyOVp1lVqovm1ctP37xDqyCRoonzzKFqpCGvgOWYud1IuIiA8EPphCkKWLl4C-_TniRj4ARePgZ2kIrQTsEx45AObg1C4LEg0YANHJKnKPI8NnhUDXmyHbC3ipxMdiDWwIxeE3HUDpvLIESEbkGWUxpwlt8pVnW376u78TpWlx1JnoQbC544dqAWihq4WJYQ1qUlWVGROsFlgHVq0Gk6leg4ti9ZGTYy8NPLMpGVd5JaJSzivcwJNw8pLPFUeRu_-kO-qsqiajy7byn232WXdl2yzjfy7aTZv8rX9lAgSbFFKBwMeDUXX9n1X1b8wgvLYQ4495LmHPPYYKG2k2sP-X8APqV6HYg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>INNV-13. PREDICTION OF MGMT METHYLATION FOR GLIOBLASTOMAS USING AI MODELS. A COST-EFFECTIVE FRAMEWORK FOR LOW AND MIDDLE-INCOME COUNTRIES</title><source>PubMed Central (PMC)</source><source>Oxford Journals Online</source><creator>Restini, Felipe ; Yoshimoto, Fernanda Hayashida ; de Brito, Leticia Hernandes ; Vaz Nascimento, José Eduardo ; Mancini, Anselmo ; Mendes de Sousa, Cecilia Feliz Penido ; Starling, Maria Thereza Mansur ; Hanna, Samir Abdallah ; Marta, Gustavo Nader ; Neves Junior, Wellington Furtado Pimenta</creator><creatorcontrib>Restini, Felipe ; Yoshimoto, Fernanda Hayashida ; de Brito, Leticia Hernandes ; Vaz Nascimento, José Eduardo ; Mancini, Anselmo ; Mendes de Sousa, Cecilia Feliz Penido ; Starling, Maria Thereza Mansur ; Hanna, Samir Abdallah ; Marta, Gustavo Nader ; Neves Junior, Wellington Furtado Pimenta</creatorcontrib><description>Abstract BACKGROUND MGMT methylation (MGMTmet) is prognostic and predictive for patients with glioblastoma (GBM). However, financial constraints limit access to molecular tests, especially in low and middle-income countries. Artificial intelligence (AI) tools have emerged as a potentially cost-effective solution for identifying MGMTmet. Therefore, we are investigating if an AI model could select those at higher risk to present positive results for molecular confirmation, thus making a better resource allocation. METHODS We have selected GBM patients from the public image bank, The Cancer Imaging Archive, and we included all patients with a molecular evaluation of MGMTmet. We defined our volume of interest based on the ESTRO-ACROP 2016 guideline for GBM radiotherapy contouring and then extracted the radiomic features. The collected features underwent structured analysis, and a prediction model for MGMTmet was developed. We used a Random Forest algorithm to identify the most relevant features. Subsequently, the dataset was divided into training and validation sets. RESULTS We examined 100 patients with histologically classified high-grade gliomas and wild-type IDH, Sixty-one were unmethylated, and 39 were methylated. In this cohort, over 39,000 features were extracted. To avoid noise and overfitting, the 13 most predictive features were selected. They belong to the following feature classes: demographic, first order, Gray Level Size Zone Matrix, and Gray Level Co-occurrence Matrix. The preliminary model achieved an accuracy of 80% for predicting MGMTmet. CONCLUSION our preliminary results show a promising role for AI models in screening patients for molecular testing. This initiative demonstrates the utilization of research to bridge the public health gap. By sharing experiences and fostering collaboration, physicians can work towards mitigating healthcare inequalities in low-middle-income countries. In our future perspectives, we plan to enhance the algorithm's efficacy by incorporating qualitative human-generated features and expanding our sample size.</description><identifier>ISSN: 1522-8517</identifier><identifier>EISSN: 1523-5866</identifier><identifier>DOI: 10.1093/neuonc/noad179.0602</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Innovations in Patient Care</subject><ispartof>Neuro-oncology (Charlottesville, Va.), 2023-11, Vol.25 (Supplement_5), p.v158-v159</ispartof><rights>The Author(s) 2023. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10639888/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10639888/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27922,27923,53789,53791</link.rule.ids></links><search><creatorcontrib>Restini, Felipe</creatorcontrib><creatorcontrib>Yoshimoto, Fernanda Hayashida</creatorcontrib><creatorcontrib>de Brito, Leticia Hernandes</creatorcontrib><creatorcontrib>Vaz Nascimento, José Eduardo</creatorcontrib><creatorcontrib>Mancini, Anselmo</creatorcontrib><creatorcontrib>Mendes de Sousa, Cecilia Feliz Penido</creatorcontrib><creatorcontrib>Starling, Maria Thereza Mansur</creatorcontrib><creatorcontrib>Hanna, Samir Abdallah</creatorcontrib><creatorcontrib>Marta, Gustavo Nader</creatorcontrib><creatorcontrib>Neves Junior, Wellington Furtado Pimenta</creatorcontrib><title>INNV-13. PREDICTION OF MGMT METHYLATION FOR GLIOBLASTOMAS USING AI MODELS. A COST-EFFECTIVE FRAMEWORK FOR LOW AND MIDDLE-INCOME COUNTRIES</title><title>Neuro-oncology (Charlottesville, Va.)</title><description>Abstract BACKGROUND MGMT methylation (MGMTmet) is prognostic and predictive for patients with glioblastoma (GBM). However, financial constraints limit access to molecular tests, especially in low and middle-income countries. Artificial intelligence (AI) tools have emerged as a potentially cost-effective solution for identifying MGMTmet. Therefore, we are investigating if an AI model could select those at higher risk to present positive results for molecular confirmation, thus making a better resource allocation. METHODS We have selected GBM patients from the public image bank, The Cancer Imaging Archive, and we included all patients with a molecular evaluation of MGMTmet. We defined our volume of interest based on the ESTRO-ACROP 2016 guideline for GBM radiotherapy contouring and then extracted the radiomic features. The collected features underwent structured analysis, and a prediction model for MGMTmet was developed. We used a Random Forest algorithm to identify the most relevant features. Subsequently, the dataset was divided into training and validation sets. RESULTS We examined 100 patients with histologically classified high-grade gliomas and wild-type IDH, Sixty-one were unmethylated, and 39 were methylated. In this cohort, over 39,000 features were extracted. To avoid noise and overfitting, the 13 most predictive features were selected. They belong to the following feature classes: demographic, first order, Gray Level Size Zone Matrix, and Gray Level Co-occurrence Matrix. The preliminary model achieved an accuracy of 80% for predicting MGMTmet. CONCLUSION our preliminary results show a promising role for AI models in screening patients for molecular testing. This initiative demonstrates the utilization of research to bridge the public health gap. By sharing experiences and fostering collaboration, physicians can work towards mitigating healthcare inequalities in low-middle-income countries. In our future perspectives, we plan to enhance the algorithm's efficacy by incorporating qualitative human-generated features and expanding our sample size.</description><subject>Innovations in Patient Care</subject><issn>1522-8517</issn><issn>1523-5866</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqNkd1OgzAYQInRxDl9Am_6ArCWQleuDEJhjUANsC1eNfzqzAYLOBMfwbeWjcXEO6_6pV_OSb4cRblHUEPQwrOmOrRNMWvarERzS4ME6hfKBJk6Vk1KyOVp1lVqovm1ctP37xDqyCRoonzzKFqpCGvgOWYud1IuIiA8EPphCkKWLl4C-_TniRj4ARePgZ2kIrQTsEx45AObg1C4LEg0YANHJKnKPI8NnhUDXmyHbC3ipxMdiDWwIxeE3HUDpvLIESEbkGWUxpwlt8pVnW376u78TpWlx1JnoQbC544dqAWihq4WJYQ1qUlWVGROsFlgHVq0Gk6leg4ti9ZGTYy8NPLMpGVd5JaJSzivcwJNw8pLPFUeRu_-kO-qsqiajy7byn232WXdl2yzjfy7aTZv8rX9lAgSbFFKBwMeDUXX9n1X1b8wgvLYQ4495LmHPPYYKG2k2sP-X8APqV6HYg</recordid><startdate>20231110</startdate><enddate>20231110</enddate><creator>Restini, Felipe</creator><creator>Yoshimoto, Fernanda Hayashida</creator><creator>de Brito, Leticia Hernandes</creator><creator>Vaz Nascimento, José Eduardo</creator><creator>Mancini, Anselmo</creator><creator>Mendes de Sousa, Cecilia Feliz Penido</creator><creator>Starling, Maria Thereza Mansur</creator><creator>Hanna, Samir Abdallah</creator><creator>Marta, Gustavo Nader</creator><creator>Neves Junior, Wellington Furtado Pimenta</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20231110</creationdate><title>INNV-13. PREDICTION OF MGMT METHYLATION FOR GLIOBLASTOMAS USING AI MODELS. A COST-EFFECTIVE FRAMEWORK FOR LOW AND MIDDLE-INCOME COUNTRIES</title><author>Restini, Felipe ; Yoshimoto, Fernanda Hayashida ; de Brito, Leticia Hernandes ; Vaz Nascimento, José Eduardo ; Mancini, Anselmo ; Mendes de Sousa, Cecilia Feliz Penido ; Starling, Maria Thereza Mansur ; Hanna, Samir Abdallah ; Marta, Gustavo Nader ; Neves Junior, Wellington Furtado Pimenta</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1842-cd00f6f6ace67635c32098e52382b0998f4f64bd4ba58dfcb953d07fb60549bd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Innovations in Patient Care</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Restini, Felipe</creatorcontrib><creatorcontrib>Yoshimoto, Fernanda Hayashida</creatorcontrib><creatorcontrib>de Brito, Leticia Hernandes</creatorcontrib><creatorcontrib>Vaz Nascimento, José Eduardo</creatorcontrib><creatorcontrib>Mancini, Anselmo</creatorcontrib><creatorcontrib>Mendes de Sousa, Cecilia Feliz Penido</creatorcontrib><creatorcontrib>Starling, Maria Thereza Mansur</creatorcontrib><creatorcontrib>Hanna, Samir Abdallah</creatorcontrib><creatorcontrib>Marta, Gustavo Nader</creatorcontrib><creatorcontrib>Neves Junior, Wellington Furtado Pimenta</creatorcontrib><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Restini, Felipe</au><au>Yoshimoto, Fernanda Hayashida</au><au>de Brito, Leticia Hernandes</au><au>Vaz Nascimento, José Eduardo</au><au>Mancini, Anselmo</au><au>Mendes de Sousa, Cecilia Feliz Penido</au><au>Starling, Maria Thereza Mansur</au><au>Hanna, Samir Abdallah</au><au>Marta, Gustavo Nader</au><au>Neves Junior, Wellington Furtado Pimenta</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>INNV-13. PREDICTION OF MGMT METHYLATION FOR GLIOBLASTOMAS USING AI MODELS. A COST-EFFECTIVE FRAMEWORK FOR LOW AND MIDDLE-INCOME COUNTRIES</atitle><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle><date>2023-11-10</date><risdate>2023</risdate><volume>25</volume><issue>Supplement_5</issue><spage>v158</spage><epage>v159</epage><pages>v158-v159</pages><issn>1522-8517</issn><eissn>1523-5866</eissn><abstract>Abstract BACKGROUND MGMT methylation (MGMTmet) is prognostic and predictive for patients with glioblastoma (GBM). However, financial constraints limit access to molecular tests, especially in low and middle-income countries. Artificial intelligence (AI) tools have emerged as a potentially cost-effective solution for identifying MGMTmet. Therefore, we are investigating if an AI model could select those at higher risk to present positive results for molecular confirmation, thus making a better resource allocation. METHODS We have selected GBM patients from the public image bank, The Cancer Imaging Archive, and we included all patients with a molecular evaluation of MGMTmet. We defined our volume of interest based on the ESTRO-ACROP 2016 guideline for GBM radiotherapy contouring and then extracted the radiomic features. The collected features underwent structured analysis, and a prediction model for MGMTmet was developed. We used a Random Forest algorithm to identify the most relevant features. Subsequently, the dataset was divided into training and validation sets. RESULTS We examined 100 patients with histologically classified high-grade gliomas and wild-type IDH, Sixty-one were unmethylated, and 39 were methylated. In this cohort, over 39,000 features were extracted. To avoid noise and overfitting, the 13 most predictive features were selected. They belong to the following feature classes: demographic, first order, Gray Level Size Zone Matrix, and Gray Level Co-occurrence Matrix. The preliminary model achieved an accuracy of 80% for predicting MGMTmet. CONCLUSION our preliminary results show a promising role for AI models in screening patients for molecular testing. This initiative demonstrates the utilization of research to bridge the public health gap. By sharing experiences and fostering collaboration, physicians can work towards mitigating healthcare inequalities in low-middle-income countries. In our future perspectives, we plan to enhance the algorithm's efficacy by incorporating qualitative human-generated features and expanding our sample size.</abstract><cop>US</cop><pub>Oxford University Press</pub><doi>10.1093/neuonc/noad179.0602</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1522-8517
ispartof Neuro-oncology (Charlottesville, Va.), 2023-11, Vol.25 (Supplement_5), p.v158-v159
issn 1522-8517
1523-5866
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10639888
source PubMed Central (PMC); Oxford Journals Online
subjects Innovations in Patient Care
title INNV-13. PREDICTION OF MGMT METHYLATION FOR GLIOBLASTOMAS USING AI MODELS. A COST-EFFECTIVE FRAMEWORK FOR LOW AND MIDDLE-INCOME COUNTRIES
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T09%3A11%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=INNV-13.%20PREDICTION%20OF%20MGMT%20METHYLATION%20FOR%20GLIOBLASTOMAS%20USING%20AI%20MODELS.%20A%20COST-EFFECTIVE%20FRAMEWORK%20FOR%20LOW%20AND%20MIDDLE-INCOME%20COUNTRIES&rft.jtitle=Neuro-oncology%20(Charlottesville,%20Va.)&rft.au=Restini,%20Felipe&rft.date=2023-11-10&rft.volume=25&rft.issue=Supplement_5&rft.spage=v158&rft.epage=v159&rft.pages=v158-v159&rft.issn=1522-8517&rft.eissn=1523-5866&rft_id=info:doi/10.1093/neuonc/noad179.0602&rft_dat=%3Coup_pubme%3E10.1093/neuonc/noad179.0602%3C/oup_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1842-cd00f6f6ace67635c32098e52382b0998f4f64bd4ba58dfcb953d07fb60549bd3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/neuonc/noad179.0602&rfr_iscdi=true